Balancing diversified cash flow against specialized biotech expansion drives investors weighing Amgen and Vertex Pharmaceuticals as healthcare options for 2027, The Motley Fool reported.
Choosing between these two companies requires analyzing distinct business models. Amgen relies on a broad portfolio spanning oncology and inflammation, while Vertex dominates specialized genetic conditions like cystic fibrosis while expanding into novel therapies.
Amgen reported revenue of approximately $38.9 billion for the 12 months ended Sept. 30, 2026, representing growth of roughly 8.3% over the prior period, alongside net income of nearly $9.4 billion. Customer concentration presents a notable structural risk for the firm, as three major distributors—McKesson Corp., Cencora Inc., and Cardinal Health—accounted for nearly 77% of its revenues in 2025.
Vertex and Amgen Differ in Genetic Targeting and Debt Levels
- Mechanism of Action: Vertex targets specific genetic drivers of diseases like cystic fibrosis, whereas Amgen manufactures a wide array of therapeutics across multiple therapeutic areas.
- Financial Leverage: Amgen utilizes significant borrowed capital, holding a debt-to-equity ratio of roughly 6.3x on its December 2025 balance sheet, compared to Vertex’s conservative 0.1x ratio.
- Regulatory Exposure: Both companies face intense pricing pressures from pharmacy benefit managers and government health programs, alongside ongoing patent and tariff negotiations.
Financial Metrics and Pipeline Expansion
Vertex Pharmaceuticals generated revenue of about $13.0 billion for the 12 months ended Sept. 30, 2026, marking growth of approximately 10.8% compared to the previous year, with net income around $4.0 billion. The company has a debt-to-equity ratio of about 0.1x, giving it strong financial leeway for its research and development pipeline.
| Metric | Amgen | Vertex Pharmaceuticals |
|---|---|---|
| Market Capitalization | $253B | $138B |
| Gross Margin | 74.00% | 85.61% |
| Forward P/E Ratio | 19.8x | 29.8x |
| Price-to-Sales Ratio | 6.5x | 10.6x |
Beyond cystic fibrosis, the company’s investigational recombinant fusion protein therapeutic, povetacicept, shows best-in-class potential for IgA nephropathy, primary membranous nephropathy, and generalized myasthenia gravis.
Amgen Manages Drug Pricing Deals and Operational Risks
Amgen faces substantial competition from biosimilars and generics that erode market share for its older products. Operational risks include depending heavily on manufacturing plants in Puerto Rico and California, along with unresolved tax disputes with the IRS.
Late last year, Amgen became one of nine companies to reach a deal with the U.S. government to lower drug prices. Under this agreement, Amgen secured an exemption from pharmaceutical tariffs for three years in exchange for reducing prices on its migraine drug Aimovig and rheumatoid arthritis medicine Amjevita by about 60% and 80%, respectively, through a direct-to-consumer platform launched in October.
Market Positioning for 2027
Amgen trades at a more affordable valuation with a Forward P/E ratio of 19.8x compared to Vertex’s 29.8x.
For fiscal 2026, Vertex sales should rise about 10% to $13.3 billion, while Amgen is projected to achieve a revenue increase of roughly 3% to $37.8 billion.
References
- Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? The Motley Fool.
